Sharemaestro company-news research for Immunitybio Inc (IBRX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest IBRX news and sentiment
Immunitybio Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
50 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone60/100
→
Published 30-day score52/100
Latest source headline
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
Stocktwits · 07 Oct 2026 03:27
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
50 current stories are mapped specifically to IBRX.
The score uses 9 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.254.
Confidence is 23/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
23/100
Confidencethin evidence
100%/100
Company news50 company stories
87/100
Story agreement13/100 difference
News history
Daily score and story count over 30 days
16 Sep01 Oct15 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence5
0.254 after freshness weightingSource breadth100
9 independent publishersCompany relevance100
share tied directly to this companyFreshness12
recency-weighted evidenceAgreement87
how closely stories agreePublisher mix62
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202658USD 10.51+2.2%
02 Oct 202659USD 10.285+21.9%
25 Sep 202653USD 8.44-0.5%
18 Sep 202647USD 8.48+7.2%
11 Sep 202652USD 7.91-2.1%
04 Sep 202651USD 8.08+0.4%
28 Aug 202653USD 8.05+3.3%
21 Aug 202657USD 7.79+2.9%
Provisional evidence
News subjects
What is shaping the score
Market update5029 stories · 58%
Earnings5211 stories · 22%
Analyst action704 stories · 8%
Balance sheet642 stories · 4%
Regulatory and legal412 stories · 4%
Guidance502 stories · 4%
Source mix
Where the evidence comes from
Stocktwits5521 stories · 42%
StocksToTrade643 stories · 6%
The Cryptonomist642 stories · 4%
AD HOC NEWS562 stories · 4%
Insider Monkey552 stories · 4%
TradingKey522 stories · 4%
Stock Titan502 stories · 4%
Recurring subjects
Subjects appearing most often
Life Sciences23Financial Markets21Earnings11Finance5Immunotherapy3Biotech3Revenue Growth2Blockchain2Technology1Shareholder1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
07 Aug50 neutral15 Oct 07:21
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 15 Oct 07:21 | 55 | -4 | 25/100 (-15) | 50 (-11) | Provisional |
| 07 Oct 23:59 | 59 | +3 | 40/100 (+2) | 61 (+1) | Measured |
| 06 Oct 23:59 | 56 | -2 | 38/100 (+1) | 60 (+3) | Measured |
| 05 Oct 23:59 | 58 | +0 | 37/100 (-4) | 57 (-2) | Measured |
| 04 Oct 23:59 | 58 | -1 | 41/100 (-6) | 59 (+1) | Measured |
| 02 Oct 23:59 | 59 | +1 | 47/100 (+6) | 58 (+7) | Measured |
| 01 Oct 23:59 | 58 | +0 | 41/100 (-2) | 51 (-1) | Measured |
| 30 Sep 23:59 | 58 | +3 | 43/100 (+11) | 52 (+8) | Measured |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 50 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Balance sheet2 stories
0.0%56.1%
Analyst action4 stories
0.0%18.2%
Regulatory and legal1 story
9.7%0.0%
Market update12 stories
4.8%3.6%
Earnings2 stories
0.0%7.7%
Each side uses the same scale: 0–56.1% of the retained directional evidence.
Where the influence comes from
56.5%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 03:27
- News subject
- Market update
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
71/100 tone
10.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 03:18
- News subject
- Analyst action
- Why this score
- Positive analyst conviction, Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 10.9% of directional evidence · 8.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
40/100 tone
ImmunityBio director Cheryl Cohen sold 81,056 shares of company stock for $851,088 on October 2, 2026, as part of a pre-established trading plan. Concurrently, she acquired 55,979 shares by exercising stock options valued at $166,817. These transactions occurred amidst significant stock p…
4% of directional evidence
Low story strength
Scoring detailsDirect company coverage
ImmunityBio director Cheryl Cohen sold 81,056 shares of company stock for $851,088 on October 2, 2026, as part of a pre-established trading plan. Concurrently, she acquired 55,979 shares by exercising stock options valued at $166,817. These transactions occurred amidst significant stock performance, with ImmunityBio also recently securing marketing authorization in the UAE for its drug ANKTIVA.
- Published
- 06 Oct 2026 22:32
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 4% of directional evidence · 8.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
EarningsNot used in direction
ImmunityBio proposes 560,000-share sale: what it means for ImmunityBio stock
ImmunityBio director Barry J. Simon has proposed selling 560,000 common shares, valued at $7.66 million, which were acquired through an open-market transaction in 2013. The biotechnology company, listed on Nasdaq under IBRX, is balancing rapid revenue growth—with second-quarter net produc…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio director Barry J. Simon has proposed selling 560,000 common shares, valued at $7.66 million, which were acquired through an open-market transaction in 2013. The biotechnology company, listed on Nasdaq under IBRX, is balancing rapid revenue growth—with second-quarter net product revenue up 92% to $50.70 million—against substantial operating losses, reporting a Q2 2026 net loss of $230.39 million. The proposed sale is a notice of intent and not a completed transaction.
- Published
- 06 Oct 2026 04:57
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 06 Oct 2026 00:52
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 20:40
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
An officer and director proposes selling 560,000 shares of ImmunityBio (NASDAQ: IBRX).
ImmunityBio officer and director Barry J. Simon has proposed to sell 560,000 common shares of the company, with an aggregate market value of $7,657,760.00. The proposed sale is scheduled for October 5, 2026, and will be handled by The Charles Schwab Corporation on the NASDAQ exchange. Thi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio officer and director Barry J. Simon has proposed to sell 560,000 common shares of the company, with an aggregate market value of $7,657,760.00. The proposed sale is scheduled for October 5, 2026, and will be handled by The Charles Schwab Corporation on the NASDAQ exchange. This Form 144 filing indicates an open-market transaction for securities originally acquired on December 31, 2013.
- Published
- 05 Oct 2026 18:57
- News subject
- Market update
- Why this score
- Business expansion, Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife SciencesFinancial Markets
—Unscored
Market updateNot used in direction
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 04 Oct 2026 23:59
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Regulatory and legalNot used in direction
IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick
ImmunityBio (IBRX) stock experienced its best week in over seven months, driven by retail investor speculation following Michael Caputo's appointment to President Trump's Cancer Panel. Investors believe this could lead to broader access for Anktiva, ImmunityBio's flagship immunotherapy. T…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio (IBRX) stock experienced its best week in over seven months, driven by retail investor speculation following Michael Caputo's appointment to President Trump's Cancer Panel. Investors believe this could lead to broader access for Anktiva, ImmunityBio's flagship immunotherapy. The company is also awaiting an FDA decision in January 2027 for an expanded label for Anktiva in bladder cancer, and its regulatory footprint has expanded to 34 countries.
- Published
- 04 Oct 2026 22:13
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
57/100 tone
0.8% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 04 Oct 2026 20:58
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.8% of directional evidence · 10.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Dow, S&P 500, Nasdaq Futures Rise As Investors Shrug Off Fed Hold, Big Tech Earnings: IBRX, MSFT, SOFI, META In Focus
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 04 Oct 2026 00:22
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
A director proposes selling 81,056 ImmunityBio (IBRX) shares, including 55,979 from option exercises.
ImmunityBio director Cheryl Cohen has proposed selling 81,056 common shares, valued at approximately $752,199.68, with an anticipated sale date of October 2, 2026. The proposed sale includes 55,979 shares from stock option exercises on the same date and 25,077 shares from restricted stock…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio director Cheryl Cohen has proposed selling 81,056 common shares, valued at approximately $752,199.68, with an anticipated sale date of October 2, 2026. The proposed sale includes 55,979 shares from stock option exercises on the same date and 25,077 shares from restricted stock units acquired on June 6, 2019. This transaction is reported via a Form 144 filing, which outlines the conditions under which restricted or insider-held shares can be publicly resold.
- Published
- 02 Oct 2026 20:25
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
74/100 tone
Analyst action
Jefferies upgrades ImmunityBio stock to Strong Buy
Jefferies has upgraded ImmunityBio stock to a Strong Buy rating, leading to an 11.77% price increase on October 2, 2026. Seven analysts have set an average target of USD 14.20, significantly above its current trading price, though analyst ratings are not unanimous. The company reported st…
5.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Jefferies has upgraded ImmunityBio stock to a Strong Buy rating, leading to an 11.77% price increase on October 2, 2026. Seven analysts have set an average target of USD 14.20, significantly above its current trading price, though analyst ratings are not unanimous. The company reported strong revenue growth in Q2 2026, driven by its lead immunotherapy ANKTIVA, but continues to face profitability challenges with a loss per share of USD 0.22.
- Published
- 02 Oct 2026 18:08
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 5.2% of directional evidence · 12.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
62/100 tone
Market update
ImmunityBio Stock Jumps: What's Going On?
ImmunityBio (IBRX) shares have been steadily rising over the past several months, with its stock chart showing a consistent upward trend despite choppy trading. The stock recently saw a sharp increase from $8.25 to $10.12 in two trading days, though the specific news driving this surge is…
0.8% of directional evidence
Low story strength
Scoring detailsDirect company coverage
ImmunityBio (IBRX) shares have been steadily rising over the past several months, with its stock chart showing a consistent upward trend despite choppy trading. The stock recently saw a sharp increase from $8.25 to $10.12 in two trading days, though the specific news driving this surge is not yet confirmed. Investors are now watching whether the stock can maintain its position above the $10.12-$10.50 range, as it currently trades near this level, to determine the staying power of this recent move.
- Published
- 02 Oct 2026 17:25
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 0.8% of directional evidence · 12.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
66/100 tone
ImmunityBio Inc. (IBRX) stock has climbed over 10% after its Executive Chairman, Patrick Soon-Shiong, backed a PIPE financing in PDS Biotechnology and joined its board. While the company states its fundamentals remain unchanged, traders are speculating on future collaborations and the exp…
37.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
ImmunityBio Inc. (IBRX) stock has climbed over 10% after its Executive Chairman, Patrick Soon-Shiong, backed a PIPE financing in PDS Biotechnology and joined its board. While the company states its fundamentals remain unchanged, traders are speculating on future collaborations and the expansion of Soon-Shiong's oncology ecosystem. This move is driving bullish sentiment and technical strength in IBRX, despite the company's significant losses and cash burn.
- Published
- 02 Oct 2026 16:32
- News subject
- Balance sheet
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 37.9% of directional evidence · 12.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
57/100 tone
0.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 07:02
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 0.3% of directional evidence · 13.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
GuidanceNot used in direction
ImmunityBio (NasdaqGS:IBRX) Stock Forecast & Analyst Predictions
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 07:00
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
38/100 tone
Market update
IBRX|Immunitybio Inc|Price:10.280|Chg%:-0.005
0.5% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 07:00
- News subject
- Market update
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 0.5% of directional evidence · 13.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
ImmunityBio Shares Rise as Investors Revisit ANKTIVA Expansion and Revenue Momentum
ImmunityBio shares increased as investors re-evaluated the company's prospects, particularly regarding the expansion of ANKTIVA and potential revenue growth. The article suggests renewed investor confidence in the company's future performance.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ImmunityBio shares increased as investors re-evaluated the company's prospects, particularly regarding the expansion of ANKTIVA and potential revenue growth. The article suggests renewed investor confidence in the company's future performance.
- Published
- 01 Oct 2026 13:58
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
59/100 tone
Market update
ImmunityBio Stock Analysis: Bullish Breakout in October
ImmunityBio stock (IBRX) experienced a significant bullish breakout, closing up 6.91% at $9.44 and touching $10 intraday for the first time since March. Technical analysis indicates a strong bullish alignment across daily and hourly charts, supported by momentum indicators and institution…
0.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
ImmunityBio stock (IBRX) experienced a significant bullish breakout, closing up 6.91% at $9.44 and touching $10 intraday for the first time since March. Technical analysis indicates a strong bullish alignment across daily and hourly charts, supported by momentum indicators and institutional interest. While a short-term pullback is noted on the 15-minute chart for digestion, the overall evidence favors a continuation of the bullish trend, with key resistance levels at $9.48 and $10.05.
- Published
- 01 Oct 2026 11:25
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 0.3% of directional evidence · 14.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger Bet
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 03:18
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
GuidanceNot used in direction
IBRX Stock Quote Price and Forecast
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 20:15
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
69/100 tone
ImmunityBio Inc. (IBRX) stock is trading up after its chairman, Patrick Soon-Shiong, expanded his oncology network by leading PIPE financing into PDS Biotechnology and joining its board. This strategic move, while not immediately changing ImmunityBio's fundamentals, signals a long-term st…
0.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
ImmunityBio Inc. (IBRX) stock is trading up after its chairman, Patrick Soon-Shiong, expanded his oncology network by leading PIPE financing into PDS Biotechnology and joining its board. This strategic move, while not immediately changing ImmunityBio's fundamentals, signals a long-term strategy for collaboration within the oncology ecosystem. The stock's steady appreciation and strong intraday trends suggest institutional accumulation and interest from momentum traders.
- Published
- 30 Sep 2026 21:00
- News subject
- Market update
- Why this score
- Business expansion
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 0.5% of directional evidence · 14.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
68/100 tone
ImmunityBio stock surged over 10% on Wednesday, reaching $9.735, indicating a bullish trend supported by strong EMA alignment and positive momentum indicators. While the daily and hourly charts confirm this bullish outlook, the 15-minute chart suggests a potential short-term pause due to …
0.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
ImmunityBio stock surged over 10% on Wednesday, reaching $9.735, indicating a bullish trend supported by strong EMA alignment and positive momentum indicators. While the daily and hourly charts confirm this bullish outlook, the 15-minute chart suggests a potential short-term pause due to overbought conditions. Key resistance levels are identified at $10.24, with the $9.57–$9.74 pivot zone acting as crucial support.
- Published
- 30 Sep 2026 18:25
- News subject
- Market update
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 0.5% of directional evidence · 14.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
66/100 tone
0.3% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 16:37
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 0.3% of directional evidence · 14.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
56/100 tone
ImmunityBio Inc. (IBRX) stock rose by 11.15% due to strong commercial momentum for its immunotherapy ANKTIVA, positive analyst sentiment, and strategic corporate developments. Wall Street analysts maintain a bullish consensus with an average price target of $12.75. Despite this, the compa…
1.7% of directional evidence
Low story strength
Scoring detailsDirect company coverage
ImmunityBio Inc. (IBRX) stock rose by 11.15% due to strong commercial momentum for its immunotherapy ANKTIVA, positive analyst sentiment, and strategic corporate developments. Wall Street analysts maintain a bullish consensus with an average price target of $12.75. Despite this, the company faces risks including widening net losses, equity dilution, concentrated governance, and regulatory execution risk.
- Published
- 30 Sep 2026 17:25
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 1.7% of directional evidence · 14.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
61/100 tone
ImmunityBio Inc. (IBRX) stock has been steadily rising, driven by investor optimism following pivotal trial success and strategic moves by its Executive Chairman, Patrick Soon-Shiong. Soon-Shiong is leading a PIPE financing into PDS Biotechnology and joining its board, expanding his oncol…
18.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
ImmunityBio Inc. (IBRX) stock has been steadily rising, driven by investor optimism following pivotal trial success and strategic moves by its Executive Chairman, Patrick Soon-Shiong. Soon-Shiong is leading a PIPE financing into PDS Biotechnology and joining its board, expanding his oncology ecosystem and potentially fostering future collaborations for ImmunityBio's cancer pipeline. Despite significant financial losses and cash burn, IBRX's strong liquidity and the positive market reaction to these strategic developments are fueling its momentum, making it a "story stock" for active traders.
- Published
- 30 Sep 2026 16:25
- News subject
- Balance sheet
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 18.6% of directional evidence · 14.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)
The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July, bringing its year-to-date performance to -10.0%.…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July, bringing its year-to-date performance to -10.0%. The fund attributed the decline to an unusual liquidity-driven dislocation across higher-growth stocks rather than deterioration in the fundamentals of its portfolio companies. Despite the volatility, merger arbitrage investments contributed positively, while equity gross exposure was reduced to 100% of NAV a
- Published
- 30 Sep 2026 12:28
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechEarningsImmunotherapy
43/100 tone
0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 03:47
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- 0.1% of directional evidence · 15.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
57/100 tone
6.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 02:44
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 6.2% of directional evidence · 15.4d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
IBRX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 96 older IBRX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to IBRX, but the headline and available text are not mainly about Immunitybio Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of IBRX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.